# Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

> **NCT04776317** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 81 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** ChAdV68-S
- **BIOLOGICAL:** ChAdV68-S-TCE
- **BIOLOGICAL:** SAM-LNP-S
- **BIOLOGICAL:** SAM-LNP-S-TCE
- **OTHER:** Sodium Chloride, 0.9%

## Key facts

- **NCT ID:** NCT04776317
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-25
- **Primary completion:** 2023-09-15
- **Final completion:** 2023-09-15
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776317, "Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04776317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*